相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Neratinib-Plus-Cetuximab in Quadruple-WT (KRAS, NRAS, BRAF, PIK3CA) Metastatic Colorectal Cancer Resistant to Cetuximab or Panitumumab: NSABP FC-7, A Phase Ib Study
Samuel A. Jacobs et al.
CLINICAL CANCER RESEARCH (2021)
MOUNTAINEER:open-label, phase II study of tucatinib combined with trastuzumab for HER2-positive metastatic colorectal cancer (SGNTUC-017, trial in progress).
John H. Strickler et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Circulating tumor DNA-guided treatment with pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer: a phase 2 trial
Yoshiaki Nakamura et al.
NATURE MEDICINE (2021)
Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E-Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study
Josep Tabernero et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
HER2 Expression Is Predictive of Survival in Cetuximab Treated Patients with RAS Wild Type Metastatic Colorectal Cancer
Said A. Khelwatty et al.
CANCERS (2021)
Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial
Salvatore Siena et al.
LANCET ONCOLOGY (2021)
Exploratory biomarker analysis of DESTINY-CRC01, a phase II, multicenter, open-label study of trastuzumab deruxtecan (T-DXd, DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC)
S. Siena et al.
ANNALS OF ONCOLOGY (2021)
Bayesian monitoring of lapatinib (L) plus trastuzumab (T) treatment of HER2 positive metastatic colorectal cancer (mCRC): An observational cohort study
A. Amatu et al.
ANNALS OF ONCOLOGY (2021)
Prognostic Value and Molecular Landscape of HER2 Low-Expressing Metastatic Colorectal Cancer
Masataka Yagisawa et al.
CLINICAL COLORECTAL CANCER (2021)
NTRK fusions in colorectal cancer: clinical meaning and future perspective
Margherita Ratti et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2021)
Trastuzumab deruxtecan in patients with HER2-overexpressing locally advanced, unresectable, or metastatic colorectal cancer (mCRC): A randomized, multicenter, phase 2 study (DESTINY-CRC02).
Kanwal Pratap Singh Raghav et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Dual-targeted therapy with pyrotinib and trastuzumab for HER2-positive advanced colorectal cancer: Preliminary results from a multicenter phase 2 trial.
Ying Yuan et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Pertuzumab plus trastuzumab (P+T) in patients (Pts) with colorectal cancer (CRC) with ERBB2 amplification or overexpression: Results from the TAPUR Study.
Ranju Gupta et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
Shanu Modi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial
Yelena Y. Janjigian et al.
LANCET ONCOLOGY (2020)
Preclinical Activity of HER2-Selective Tyrosine Kinase Inhibitor Tucatinib as a Single Agent or in Combination with Trastuzumab or Docetaxel in Solid Tumor Models
Anita Kulukian et al.
MOLECULAR CANCER THERAPEUTICS (2020)
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer
Kohei Shitara et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colrectal cancer: the phase II HERACLES-B trial
Andrea Sartore-Bianchi et al.
ESMO OPEN (2020)
International Harmonization of Provisional Diagnostic Criteria for ERBB2-Amplified Metastatic Colorectal Cancer Allowing for Screening by Next-Generation Sequencing Panel
Satoshi Fujii et al.
JCO PRECISION ONCOLOGY (2020)
Loss of HER2 after HER2-targeted treatment
Tanja Ignatov et al.
BREAST CANCER RESEARCH AND TREATMENT (2019)
Plasma HER2 (ERBB2) Copy Number Predicts Response to HER2-targeted Therapy in Metastatic Colorectal Cancer
Giulia Siravegna et al.
CLINICAL CANCER RESEARCH (2019)
Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study
Funda Meric-Bemstam et al.
LANCET ONCOLOGY (2019)
Detection of ERBB2 Amplification by Next-Generation Sequencing Predicts HER2 Expression in Colorectal Carcinoma
Odise Cenaj et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2019)
Clinicopathologic Characteristics of HER2-positive Metastatic Colorectal Cancer and Detection of HER2 in Plasma Circulating Tumor DNA
Qing Wei et al.
CLINICAL COLORECTAL CANCER (2019)
[fam-] trastuzumab deruxtecan, antitumor activity is dependent on HER2 expression level rather than on HER2 amplification
Naoki Takegawa et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
HER2 Positivity Predicts Unresponsiveness to EGFR-Targeted Treatment in Metastatic Colorectal Cancer
Andrea Sartore-Bianchi et al.
ONCOLOGIST (2019)
Gene expression profiles of CMS2-epithelial/canonical colorectal cancers are largely driven by DNA copy number gains
Kaja C. G. Berg et al.
ONCOGENE (2019)
Combined targeting of HER-2 and HER-3 represents a promising therapeutic strategy in colorectal cancer
Lena-Christin Conradi et al.
BMC CANCER (2019)
Negative Hyperselection of Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer Who Received Panitumumab-Based Maintenance Therapy
Federica Morano et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
527PDTrastuzumab and tucatinib for the treatment of HER2 amplified metastatic colorectal cancer (mCRC): Initial results from the MOUNTAINEER trial
J H Strickler et al.
ANNALS OF ONCOLOGY (2019)
Immune checkpoint inhibitors for the treatment of MSI-H/MMR-D colorectal cancer and a perspective on resistance mechanisms
Ibrahim Halil Sahin et al.
BRITISH JOURNAL OF CANCER (2019)
Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity
Jacqulyne P. Robichaux et al.
CANCER CELL (2019)
HER2-targeted therapy: an emerging strategy in advanced colorectal cancer
Anna La Salvia et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2019)
Loss of HER2 positivity after anti-HER2 chemotherapy in HER2-positive gastric cancer patients: results of the GASTric cancer HER2 reassessment study 3 (GASTHER3)
Seyoung Seo et al.
GASTRIC CANCER (2019)
Precision treatment in colorectal cancer: Now and the future
Tung On Yau
JGH OPEN (2019)
KRAS-mutant (mt) colorectal cancer (CRC) organoid models generated from patient-derived xenografts (PDX) show response to combination of trametinib (Tm), neratinib (N), and trastuzumab (Tz)
Rekha Pal et al.
CANCER RESEARCH (2019)
Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer
S. Siena et al.
ANNALS OF ONCOLOGY (2018)
Targeting HER2 in Colorectal Cancer: The Landscape of Amplification and Short Variant Mutations in ERBB2 and ERBB3
Jeffrey S. Ross et al.
CANCER (2018)
Radiologic and Genomic Evolution of Individual Metastases during HER2 Blockade in Colorectal Cancer
Giulia Siravegna et al.
CANCER CELL (2018)
Prognostic and Predictive Value of HER2 Amplification in Patients With Metastatic Colorectal Cancer
Kentaro Sawada et al.
CLINICAL COLORECTAL CANCER (2018)
Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update
Antonio C. Wolff et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Brain metastasis in gastroesophageal adenocarcinoma and HER2 status
Dror Limon et al.
JOURNAL OF NEURO-ONCOLOGY (2018)
Molecular Landscape of ERBB2/ERBB3 Mutated Colorectal Cancer
Jonathan M. Loree et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
Molecular Landscape of ERBB2/ERBB3 Mutated Colorectal Cancer
Jonathan M. Loree et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
HER kinase inhibition in patients with HER2-and HER3-mutant cancers
David M. Hyman et al.
NATURE (2018)
Utility of comprehensive genomic sequencing for detecting HER2-positive colorectal cancer
Yoshifumi Shimada et al.
HUMAN PATHOLOGY (2017)
Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer A Randomized Clinical Trial
Alan P. Venook et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)
HER2 Amplification and Cetuximab Efficacy in Patients With Metastatic Colorectal Cancer Harboring Wild-type RAS and BRAF
Jae Ho Jeong et al.
CLINICAL COLORECTAL CANCER (2017)
Activating ERBB2/HER2 mutations indicate susceptibility to pan-HER inhibitors in Lynch and Lynch-like colorectal cancer
Michael Kloth et al.
GUT (2016)
HER2 genomic amplification in circulating tumor DNA from patients with cetuximab-resistant colorectal cancer
Naoki Takegawa et al.
ONCOTARGET (2016)
Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity
Yusuke Ogitani et al.
CANCER SCIENCE (2016)
HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials
Susan D. Richman et al.
JOURNAL OF PATHOLOGY (2016)
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial
Andrea Sartore-Bianchi et al.
LANCET ONCOLOGY (2016)
HER2 heterogeneity in gastric/gastroesophageal cancers: From benchside to practice
Federica Grillo et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2016)
HER2 testing in gastric cancer: An update
Lucas Faria Abrahao-Machado et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2016)
HER2 amplification as a negative predictive biomarker for anti-epidermal growth factor receptor antibody therapy in metastatic colorectal cancer.
Kanwal Pratap Singh Raghav et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
A Phase 1 Study of Cetuximab and Lapatinib in Patients With Advanced Solid Tumor Malignancies
John F. Deeken et al.
CANCER (2015)
Assessment of a HER2 scoring system for colorectal cancer: results from a validation study
Emanuele Valtorta et al.
MODERN PATHOLOGY (2015)
Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients
Giulia Siravegna et al.
NATURE MEDICINE (2015)
HER2 Activating Mutations Are Targets for Colorectal Cancer Treatment
Shyam M. Kavuri et al.
CANCER DISCOVERY (2015)
Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features
E. Missiaglia et al.
ANNALS OF ONCOLOGY (2014)
HER2/neu testing in primary colorectal carcinoma
B. Ingold Heppner et al.
BRITISH JOURNAL OF CANCER (2014)
HER2 Status in Colorectal Cancer: Its Clinical Significance and the Relationship between HER2 Gene Amplification and Expression
An Na Seo et al.
PLOS ONE (2014)
Changes in Colorectal Carcinoma Genomes under Anti-EGFR Therapy Identified by Whole-Genome Plasma DNA Sequencing
Sumitra Mohan et al.
PLOS GENETICS (2014)
Comparison of HER2 expression between primary colorectal cancer and their corresponding metastases
Won-Suk Lee et al.
CANCER MEDICINE (2014)
Comparative sequencing analysis reveals high genomic concordance between matched primary and metastatic colorectal cancer lesions
A. Rose Brannon et al.
GENOME BIOLOGY (2014)
HER2 in high-risk rectal cancer patients treated in EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab
F. Sclafani et al.
ANNALS OF ONCOLOGY (2013)
HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients
V. Martin et al.
BRITISH JOURNAL OF CANCER (2013)
HER-2 Expression in Brain Metastases from Colorectal Cancer and Corresponding Primary Tumors: A Case Cohort Series
Giuseppe Aprile et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2013)
Comprehensive molecular characterization of human colon and rectal cancer
Donna M. Muzny et al.
NATURE (2012)
Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab
Kimio Yonesaka et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
A Molecularly Annotated Platform of Patient-Derived Xenografts (Xenopatients) Identifies HER2 as an Effective Therapeutic Target in Cetuximab-Resistant Colorectal Cancer
Andrea Bertotti et al.
CANCER DISCOVERY (2011)
A phase I trial of paclitaxel and trastuzumab in combination with interleukin-12 in patients with HER2/neu-expressing malignancies
Tanios S. Bekaii-Saab et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Advanced colorectal cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up
E. J. D. Van Cutsern et al.
ANNALS OF ONCOLOGY (2008)
Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG)
BC Pestalozzi et al.
ANNALS OF ONCOLOGY (2006)
ERBB receptors and cancer: The complexity of targeted inhibitors
NE Hynes et al.
NATURE REVIEWS CANCER (2005)
Protein overexpression and gene amplification of HER-2 and EGFR in colorectal cancers:: an immunohistochemical and fluorescent in situ hybridization study
A Ooi et al.
MODERN PATHOLOGY (2004)
Low overexpression of HER-2/PPPNeu in advanced colorectal cancer limits the usefulness of trastuzumab (herceptin (R)) and irinotecan as therapy. A phase II trial
RK Ramanathan et al.
CANCER INVESTIGATION (2004)
Untangling the ErbB signalling network
Y Yarden et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2001)
分享论文
